Key Points
- Gilead CEO Daniel Patrick O'day sold 10,000 shares on April 28 at an average price of $129.16 for $1,291,600; the trade was executed under a pre-arranged Rule 10b5-1 plan and reduced his stake by 1.56% to 632,567 shares (≈$81.7M).
- Positive company catalysts include the FDA granting priority review for Gilead's once-daily bictegravir+lenacapavir HIV regimen (PDUFA in August) and completion of the ~$7.8B Arcellx acquisition, while analysts (e.g., Morgan Stanley) have raised price targets and the company recently increased its quarterly dividend to $0.82.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the transaction, the chief executive officer owned 632,567 shares of the company's stock, valued at approximately $81,702,353.72. The trade was a 1.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Daniel Patrick O'day also recently made the following trade(s):
- On Friday, February 27th, Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock. The shares were sold at an average price of $144.79, for a total value of $1,447,900.00.
- On Thursday, February 5th, Daniel Patrick O'day sold 115,640 shares of Gilead Sciences stock. The stock was sold at an average price of $150.00, for a total value of $17,346,000.00.
Gilead Sciences Stock Performance
Shares of GILD opened at $128.84 on Thursday. The stock has a market capitalization of $159.92 billion, a PE ratio of 19.03, a price-to-earnings-growth ratio of 1.69 and a beta of 0.39. The business's fifty day moving average price is $140.90 and its 200 day moving average price is $132.36. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. Gilead Sciences, Inc. has a 12-month low of $95.29 and a 12-month high of $157.29.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts forecast that Gilead Sciences, Inc. will post 8.62 EPS for the current year.
Gilead Sciences Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were given a dividend of $0.82 per share. The ex-dividend date of this dividend was Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.5%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.79. Gilead Sciences's payout ratio is currently 48.45%.
Gilead Sciences News Roundup
Here are the key news stories impacting Gilead Sciences this week:
Analyst Ratings Changes
A number of equities analysts have commented on the company. Barclays began coverage on Gilead Sciences in a research note on Friday, February 20th. They issued an "equal weight" rating and a $155.00 target price for the company. JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $150.00 to $160.00 and gave the company an "overweight" rating in a research report on Wednesday, February 11th. BMO Capital Markets increased their target price on Gilead Sciences from $135.00 to $150.00 and gave the stock an "outperform" rating in a research report on Monday, January 26th. Cantor Fitzgerald reduced their price target on shares of Gilead Sciences from $155.00 to $115.00 and set an "overweight" rating for the company in a report on Friday, April 10th. Finally, UBS Group increased their price objective on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a "buy" rating in a report on Monday, January 26th. Twenty-four investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $157.35.
Read Our Latest Stock Analysis on Gilead Sciences
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in GILD. Brighton Jones LLC grew its position in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after buying an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new stake in shares of Gilead Sciences during the 4th quarter worth about $215,000. Sivia Capital Partners LLC lifted its stake in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company's stock worth $464,000 after acquiring an additional 602 shares during the period. Ieq Capital LLC lifted its stake in shares of Gilead Sciences by 12.0% in the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company's stock worth $13,160,000 after acquiring an additional 12,705 shares during the period. Finally, Diversify Advisory Services LLC boosted its holdings in shares of Gilead Sciences by 18.6% in the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company's stock valued at $516,000 after acquiring an additional 674 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.
Gilead Sciences Company Profile
(
Get Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
